NASDAQ · Biotechnology

GH Research PLC (GHRS)

$28.33 -1.22%
49 In band Daily RSI (14) · 21 Aug 2026

Moving averages

SMA 200$18.50+53.14%

Company profile

GH Research PLC is a pioneering clinical-stage biopharmaceutical company focused on developing psilocybin-based therapies for psychiatric and neurodegenerative disorders. The company's robust pipeline addresses critical unmet needs in mental health treatment, underscored by a commitment to innovative therapeutic solutions led by a seasoned management team. By harnessing its proprietary scientific approach, GH Research is strategically positioned to disrupt current treatment paradigms and enhance patient outcomes, establishing itself as a prospective leader in the rapidly evolving mental health therapeutics sector.

SectorHealthcare
IndustryBiotechnology
Market cap$2.08B
P/E ratioNone
EPS$-1.03
Beta1.29
Dividend yield0.00%
52-week high$31.44
52-week low$11.83

Similar stocks in Biotechnology

Free forever

RSI alerts for GHRS

Get an email the moment GH Research PLC crosses into oversold or overbought territory. Nothing else, ever.

Add alert

Data last updated 14 August 2026 at 6:10 AM EDT